To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• willing and able to provide written informed consent

• age 20 years or older

• patient with congestive heart failure, taking treatment medicine and NYHA grade II~III

• patient with hypertension, taking treatment medicine or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit

Exclusion Criteria:

• Known or suspected secondary hypertension(ex. aortic coactation, primary hyperaldosteronism, renal artery stenosis, pheochromocytoma, cushing syndrome, polycystic renal disease)

• blood creatinine level ≥ 2.5mg/dl

• blood potassium level > 5.5mEq/L

• blood SGOT, SGPT level ≥ maximum normal range X3 or patient with sever hepatic dysfunction, cholestasis

• pregnant or breast-feeding

• premenopausal women not using adequate contraception

• patient has history about hypersensitivity or taboo of investigational product

• patient with lactose intolerance or Lapp lactase deficiency or glucode-galactose malabsorption

• administration of other study drugs within 1 month prior to screening

• history of ischemic heart disease(ex. angina pectoris, myocardial infarction) within the last 3 months

• in investigator's judgement